|
|
(24 intermediate revisions by 4 users not shown) |
Line 1: |
Line 1: |
| {{SubstanceBox | | {{approval}} |
| | {{stub}} |
| | {{SummarySheet}} |
| | {{SubstanceBox/LAE-32}} |
|
| |
|
| <!-- Special Parameters -->
| | '''Lysergic acid ethylamide''' (also known as '''LAE-32''', '''LAE''', and '''d-ethyllysergamide''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class. It is one of the least known and least researched psychedelic substances. |
| |displayClasses={{{displayClasses|}}}
| |
| |MaterialTable_MaxWidth=250px
| |
| |MaterialTable_Title={{PAGENAME}}
| |
|
| |
|
| <!-- Modules -->
| | The pharmacology of LAE-32 is complex{{citation needed}}, but it acts primarily by binding to [[serotonin]] [[receptors]] in the brain, much like LSD and other serotonergic psychedelics.{{citation needed}} |
| |ModuleSource=false
| |
| |ModuleCombination=false
| |
| |ModuleStructure=true
| |
| |ModuleNomenclature=true
| |
| |ModuleClassMembership=true
| |
| |ModuleROA=true
| |
|
| |
|
| <!-- Source -->
| | ==History and culture== |
| |PhotoImageFile=
| | {{historyStub}} |
| |PhotoImageWidth=
| | ===The CIA and Project MKULTRA Findings=== |
| |PhotoImageCaption=
| | LAE-32 was experimented with by the CIA as part of Project MKULTRA. It was reported to create a condition similar to that of schizophrenia in mentally healthy individuals, characterized by indifference and depersonalization. While it was reported that, when used on schizophrenics, it created a condition that allowed the patients to become indifferent to their hallucinations and cease hallucinatory excitation. |
|
| |
|
| <!-- Combination -->
| | ==Chemistry== |
| |CombinationImage1_Caption=
| | LAE-32, or d-lysergic acid ethylamide, is a semisynthetic substance of the [[lysergamide]] family. |
| |CombinationImage1_File=
| |
| |CombinationImage1_Width=
| |
|
| |
|
| |CombinationImage2_Caption=
| | Its chemical structure consists of a bicyclic hexahydroindole ring fused to a bicyclic quinoline group (lysergic acid). At carbon 8 of the quinoline an N, generally N-ethyl carboxamide is bound, LAE-32 is additionally substituted at carbon 6 with a methyl group. |
| |CombinationImage2_File=
| |
| |CombinationImage2_Width=
| |
|
| |
|
| |CombinationImage3_Caption=
| | ==Pharmacology== |
| |CombinationImage3_File=
| | {{Further|Serotonergic psychedelic}} |
| |CombinationImage3_Width=
| | LAE-32 most likely acts by binding to serotonin receptors in the brain. It may, like [[LSD]], bind to dopamine receptors as well. |
|
| |
|
| <!-- Structure -->
| | ==Subjective effects== |
| |MolecularStructureCaption=Molecular structure of lysergic acid ethylamide
| | The subjective effects of LAE-32 are reportedly mainly sedating and depersonalizing, creating a state of indifference in users. |
| |SkeletalImageFile=File:LAE-32.svg
| |
| |SkeletalImageWidth=245px
| |
| |3DImageFile=
| |
| |3DImageWidth=
| |
|
| |
|
| <!-- Nomenclature -->
| | {{Preamble/SubjectiveEffects}} |
| |NameCommon=LAE-32, LAE
| | {{effects/base |
| |NameSubstitution=d-Lysergic acid ethylamide
| |
| |NameSystematic=N-ethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
| |
|
| |
|
| <!-- Class Membership -->
| | |{{effects/physical| |
| |EffectClass=[[psychoactive class::Psychedelic]]
| |
| |ChemicalClass=[[chemical class::Lysergamide]]
| |
|
| |
|
| <!-- Dosage/Duration per ROA -->
| | *'''[[Effect::Pupil dilation]]''' |
| | *'''[[Effect::Sedation]]''' - This effect is mild compared to traditional [[sedatives]] such as [[barbiturates]] and [[benzodiazepines]]. |
| | }} |
| | |{{effects/cognitive| |
|
| |
|
| |OralROA=false
| | *'''[[Effect::Personal bias suppression]]''' |
| |OralROA_Collapsed=true
| | *'''[[Effect::Motivation suppression]]''' - LAE-32 is unique among psychedelics for its ability to suppress willpower. |
| |OralROA_Caption=
| | *'''[[Effect::Personality regression]]''' |
| |OralROA_Bioavailability=
| |
| |OralROA_Threshold=
| |
| |OralROA_Light=
| |
| |OralROA_Common=
| |
| |OralROA_Strong=
| |
| |OralROA_Heavy=
| |
| |OralROA_TimelineFile=
| |
| |OralROA_TimelineWidth=
| |
| |OralROA_Duration=
| |
| |OralROA_Onset=
| |
| |OralROA_Comeup=
| |
| |OralROA_Peak=
| |
| |OralROA_Offset=
| |
| |OralROA_Aftereffects=
| |
|
| |
|
| |SublingualROA=true
| | }} |
| |SublingualROA_Collapsed=false
| | }} |
| |SublingualROA_Caption=
| | ===Dangerous interactions=== |
| |SublingualROA_Bioavailability=
| | {{DangerousInteractions/Intro}} |
| |SublingualROA_Microdose=
| |
| |SublingualROA_Threshold=[[Sublingual threshold dose::0.5-1.5]] [[Sublingual dose units::mg]]
| |
| |SublingualROA_Light=
| |
| |SublingualROA_Common=
| |
| |SublingualROA_Strong=
| |
| |SublingualROA_Heavy=
| |
| |SublingualROA_TimelineFile=
| |
| |SublingualROA_TimelineWidth=
| |
| |SublingualROA_Duration=
| |
| |SublingualROA_Onset=
| |
| |SublingualROA_Comeup=
| |
| |SublingualROA_Peak=
| |
| |SublingualROA_Offset=
| |
| |SublingualROA_Aftereffects=
| |
|
| |
|
| |BuccalROA=false
| | *'''[[UncertainInteraction::Cannabis]]''' - Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like [[anxiety]], [[confusion]] and [[psychosis]]. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake. |
| |BuccalROA_Collapsed=true
| | *'''[[UncertainInteraction::Amphetamines]]''' & '''[[UncertainInteraction::Cocaine]]''' - Stimulants increase [[anxiety]] levels and the risk of [[thought loops]] which can lead to negative experiences. |
| |BuccalROA_Caption=Presumes no tolerance
| | *'''[[UnsafeInteraction::Tramadol]]''' - Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures. |
| |BuccalROA_Bioavailability=
| |
| |BuccalROA_Threshold=< x mg
| |
| |BuccalROA_Light=x - x mg
| |
| |BuccalROA_Common=x - x mg
| |
| |BuccalROA_Strong=x - x mg
| |
| |BuccalROA_Heavy= > mg
| |
| |BuccalROA_TimelineFile=
| |
| |BuccalROA_TimelineWidth=
| |
| |BuccalROA_Duration=x - x hours
| |
| |BuccalROA_Onset=x minutes
| |
| |BuccalROA_Peak=x hours
| |
| |BuccalROA_Offset=x hours
| |
| |BuccalROA_Aftereffects=x hours
| |
|
| |
|
| |InsufflatedROA=false
| | ==Legal status== |
| |InsufflatedROA_Collapsed=true
| | LAE-32 is not explicitly illegal in any nation, but it is possibly illegal to possess in the United States for purposes of consumption due to the Federal Analog Act. |
| |InsufflatedROA_Caption=
| |
| |InsufflatedROA_Bioavailability=
| |
| |InsufflatedROA_Threshold=< x mg
| |
| |InsufflatedROA_Light=x - x mg
| |
| |InsufflatedROA_Common=x - x mg
| |
| |InsufflatedROA_Strong=x - x mg
| |
| |InsufflatedROA_Heavy= > mg
| |
| |InsufflatedROA_TimelineFile=
| |
| |InsufflatedROA_TimelineWidth=
| |
| |InsufflatedROA_Duration=x - x hours
| |
| |InsufflatedROA_Onset=x minutes
| |
| |InsufflatedROA_Peak=x hours
| |
| |InsufflatedROA_Offset=x hours
| |
| |InsufflatedROA_Aftereffects=x hours
| |
|
| |
|
| |RectalROA=false
| | ==See also== |
| |RectalROA_Collapsed=true
| | * [[Responsible use (Hallucinogens)]] |
| |RectalROA_Caption=Presumes no tolerance
| | * [[Psychedelics]] |
| |RectalROA_Bioavailability=
| | * [[Lysergamide]] |
| |RectalROA_Threshold=< x mg
| | * [[LSD]] |
| |RectalROA_Light=x - x mg
| | * [[Psilocin]] |
| |RectalROA_Common=x - x mg
| | * [[Mescaline]] |
| |RectalROA_Strong=x - x mg
| |
| |RectalROA_Heavy= > mg
| |
| |RectalROA_TimelineFile=
| |
| |RectalROA_TimelineWidth=
| |
| |RectalROA_Duration=x - x hours
| |
| |RectalROA_Onset=x minutes
| |
| |RectalROA_Peak=x hours
| |
| |RectalROA_Offset=x hours
| |
| |RectalROA_Aftereffects=x hours
| |
|
| |
|
| |TransdermalROA=false
| | ==External links== |
| |TransdermalROA_Collapsed=true
| | * [https://en.wikipedia.org/wiki/LAE-32 LAE-32 (Wikipedia)] |
| |TransdermalROA_Caption=Presumes no tolerance
| | * [https://imgur.com/a/Y4CTo Project MKULTRA: LSD and LAE-32 (Imgur images of declassified CIA MKULTRA documents)] |
| |TransdermalROA_Bioavailability=
| | * [https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5311 LAE-32 (TiHKAL / Isomer Design)] |
| |TransdermalROA_Threshold=< x mg
| |
| |TransdermalROA_Light=x - x mg
| |
| |TransdermalROA_Common=x - x mg
| |
| |TransdermalROA_Strong=x - x mg
| |
| |TransdermalROA_Heavy= > mg
| |
| |TransdermalROA_TimelineFile=
| |
| |TransdermalROA_TimelineWidth=
| |
| |TransdermalROA_Duration=x - x hours
| |
| |TransdermalROA_Onset=x minutes
| |
| |TransdermalROA_Peak=x hours
| |
| |TransdermalROA_Offset=x hours
| |
| |TransdermalROA_Aftereffects=x hours
| |
|
| |
|
| |SubcutaneousROA=false
| | ==References== |
| |SubcutaneousROA_Collapsed=true
| | {{reflist|2}} |
| |SubcutaneousROA_Caption=Presumes no tolerance
| | [[Category:Psychoactive substance]] |
| |SubcutaneousROA_Bioavailability=
| | [[Category:Entheogen]] |
| |SubcutaneousROA_Threshold=< x mg
| | [[Category:Hallucinogen]] |
| |SubcutaneousROA_Light=x - x mg
| | [[Category:Psychedelic]] |
| |SubcutaneousROA_Common=x - x mg
| | [[Category:Lysergamide]] |
| |SubcutaneousROA_Strong=x - x mg
| | [[Category:Approval]] |
| |SubcutaneousROA_Heavy= > mg
| | [[Category:Proofread]] |
| |SubcutaneousROA_TimelineFile=
| | {{#set:Featured=true}} |
| |SubcutaneousROA_TimelineWidth=
| |
| |SubcutaneousROA_Duration=x - x hours
| |
| |SubcutaneousROA_Onset=x minutes
| |
| |SubcutaneousROA_Peak=x hours
| |
| |SubcutaneousROA_Offset=x hours
| |
| |SubcutaneousROA_Aftereffects=x hours
| |
| | |
| |IntramuscularROA=false
| |
| |IntramuscularROA_Collapsed=true
| |
| |IntramuscularROA_Caption=Presumes no tolerance
| |
| |IntramuscularROA_Bioavailability=
| |
| |IntramuscularROA_Threshold=< x mg
| |
| |IntramuscularROA_Light=x - x mg
| |
| |IntramuscularROA_Common=x - x mg
| |
| |IntramuscularROA_Strong=x - x mg
| |
| |IntramuscularROA_Heavy= > mg
| |
| |IntramuscularROA_TimelineFile=
| |
| |IntramuscularROA_TimelineWidth=
| |
| |IntramuscularROA_Duration=x - x hours
| |
| |IntramuscularROA_Onset=x minutes
| |
| |IntramuscularROA_Peak=x hours
| |
| |IntramuscularROA_Offset=x hours
| |
| |IntramuscularROA_Aftereffects=x hours
| |
| | |
| |IntravenousROA=false
| |
| |IntravenousROA_Collapsed=true
| |
| |IntravenousROA_Caption=Presumes no tolerance
| |
| |IntravenousROA_Bioavailability=
| |
| |IntravenousROA_Threshold=< x mg
| |
| |IntravenousROA_Light=x - x mg
| |
| |IntravenousROA_Common=x - x mg
| |
| |IntravenousROA_Strong=x - x mg
| |
| |IntravenousROA_Heavy= > mg
| |
| |IntravenousROA_TimelineFile=
| |
| |IntravenousROA_TimelineWidth=
| |
| |IntravenousROA_Duration=x - x hours
| |
| |IntravenousROA_Onset=x minutes
| |
| |IntravenousROA_Peak=x hours
| |
| |IntravenousROA_Offset=x hours
| |
| |IntravenousROA_Aftereffects=x hours
| |
| }}
| |
| {{SummarySheet}} | |
| | |
| '''Lysergic acid ethylamide''' (also known as '''LAE-32''', '''LAE''', and '''d-ethyllysergamide''') is a semisynthetic [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class.
| |
| LAE-32 is one of the least known and least researched psychedelic substances.
| |
| The pharmacology of LAE-32 is complex{{citation needed}}, but it acts primarily by binding to [[serotonin]] [[receptors]] in the brain, much like LSD and other serotonergic psychedelics.{{citation needed}}
| |